Related references
Note: Only part of the references are listed.Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database
J. Puetz et al.
HAEMOPHILIA (2014)
Computational modelling and inhibitor risk: predicting the future?
D. P. Hart
HAEMOPHILIA (2014)
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw et al.
BLOOD (2013)
The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource
Amanda B. Payne et al.
HUMAN MUTATION (2013)
NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ
Edita Karosiene et al.
IMMUNOGENETICS (2013)
HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity
Sinu Paul et al.
JOURNAL OF IMMUNOLOGY (2013)
A Gene-Specific Method for Predicting Hemophilia-Causing Point Mutations
Nobuko Hamasaki-Katagiri et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B
P. M. Rallapalli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A
Gouri Shankar Pandey et al.
NATURE MEDICINE (2013)
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B
Claudia Pamela Radic et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory AntiFactor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
Gouri Shankar Pandey et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
The CDC Hemophilia B mutation project mutation list: a new online resource
Tengguo Li et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2013)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw et al.
BLOOD (2012)
Haemophilia B: current pharmacotherapy and future directions
Massimo Franchini et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
A study of variations in the reported haemophilia B prevalence around the world
J. S. Stonebraker et al.
HAEMOPHILIA (2012)
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity
C. H. Miller et al.
HAEMOPHILIA (2012)
HLArestrictor-a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides
Malene Erup Larsen et al.
IMMUNOGENETICS (2011)
SFmap: a web server for motif analysis and prediction of splicing factor binding sites
Inbal Paz et al.
NUCLEIC ACIDS RESEARCH (2010)
Hemophilia: New Protein Therapeutics
Steven W. Pipe
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
M. Chitlur et al.
HAEMOPHILIA (2009)
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
A. Pavlova et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Human Splicing Finder: an online bioinformatics tool to predict splicing signals
Francois-Olivier Desmet et al.
NUCLEIC ACIDS RESEARCH (2009)
The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment
Samantha C. Gouw et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2009)
A computational approach for genome-wide mapping of splicing factor binding sites
Martin Akerman et al.
GENOME BIOLOGY (2009)
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice
P. C. Ter Avest et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
S. C. Gouw et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors
Birgit M. Reipert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
Jan Astermark et al.
BLOOD (2006)
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
J Astermark et al.
BLOOD (2006)
Characterization and prediction of alternative splice sites
M Wang et al.
GENE (2006)
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
SC Darby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development
J Astermark et al.
HAEMOPHILIA (2001)
Haemophilia B mutations in Sweden:: a population-based study of mutational heterogeneity
R Ljung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
